Literature DB >> 10855998

Impact of HAART on causes of death of persons with late-stage AIDS.

G R Sansone1, J D Frengley.   

Abstract

CONTEXT: The increasing use of highly active antiretroviral therapies (HAARTs) has changed the course of AIDS-related illnesses and enhanced the quality of life of patients infected with human immunodeficiency virus (HIV) and may have changed the causes of deaths in patients with acquired immunodeficiency syndrome (AIDS).
OBJECTIVE: The aim of the present study was to investigate causes of deaths in long-term care hospital patients with late-stage AIDS who expired at the Coler-Goldwater Memorial Hospital in New York City in 1995, and in 1998 and 1999, that is, immediately before and the two most recent years after the advent of HAART.
METHODS: Analysis of causes of deaths as recorded on the death certificates of 232 AIDS patients.
RESULTS: The overall mortality rate declined from 75.6 deaths per 100 person-years in 1995 to 33.2 deaths per 100 person-years in 1998-1999 (P < .001). The number of AIDS patients who expired because of sepsis and opportunistic infections, which included Pneumocystis carinii pneumonia (PCP), decreased significantly from 30 (26.1%) and 24 (20.9%) in 1995 to 15 (12.8%) and 10 (8.5%) in 1998-1999, respectively (P < .05). In contrast, deaths from hepatic failure increased from 0 (0%) in 1995 to 7 (6%) in 1998-1999 (P < .05). Increases, although not significant statistically, were associated with pneumonias excluding PCP, end-stage AIDS, renal failure, and malignancies. Analysis of cause-specific mortality by gender between 1995 and 1998-1999 revealed very little difference between men and women. This analysis showed, however, that the infectious processes taken together (pneumonias excluding PCP, sepsis, and opportunistic infections including PCP) were significantly less frequent causes of death in 1998-1999 than in 1995 (P < .01).
CONCLUSION: These findings indicate that HAART affected the causes of deaths in patients with AIDS, with "traditional" opportunistic infections diminishing in importance relative to chronic medical conditions and malignancies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10855998      PMCID: PMC3456132          DOI: 10.1007/bf02390528

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  24 in total

1.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

Authors:  R S Hogg; K V Heath; B Yip; K J Craib; M V O'Shaughnessy; M T Schechter; J S Montaner
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

2.  Improving cause-of-death statistics.

Authors:  H M Rosenberg
Journal:  Am J Public Health       Date:  1989-05       Impact factor: 9.308

3.  Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort.

Authors:  G J Dore; J F Hoy; S A Mallal; Y Li; A M Mijch; M A French; D A Cooper; J M Kaldor
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-09-01

4.  Causes of death of HIV-infected persons in Ottawa, Ontario, 1984-1995.

Authors:  S Kravcik; N Hawley-Foss; G Victor; J B Angel; G E Garber; S Pagé; N Denommé; L O'Reilly; D W Cameron
Journal:  Arch Intern Med       Date:  1997-10-13

5.  Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.

Authors:  H R Brodt; B S Kamps; P Gute; B Knupp; S Staszewski; E B Helm
Journal:  AIDS       Date:  1997-11-15       Impact factor: 4.177

6.  Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patients.

Authors:  R P Brettle; A Wilson; S Povey; S Morris; R Morgan; C L Leen; S Hutchinson; S Lewis; S Gore
Journal:  Int J STD AIDS       Date:  1998-02       Impact factor: 1.359

7.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

8.  Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.

Authors:  J A Bartlett; S L Benoit; V A Johnson; J B Quinn; G E Sepulveda; W C Ehmann; C Tsoukas; M A Fallon; P L Self; M Rubin
Journal:  Ann Intern Med       Date:  1996-08-01       Impact factor: 25.391

Review 9.  Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.

Authors:  M A Jacobson; M French
Journal:  AIDS       Date:  1998       Impact factor: 4.177

10.  Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992.

Authors:  R M Selik; S Y Chu; J W Ward
Journal:  Ann Intern Med       Date:  1995-12-15       Impact factor: 25.391

View more
  3 in total

1.  Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy.

Authors:  Mardge H Cohen; Audrey L French; Lorie Benning; Andrea Kovacs; Kathryn Anastos; Mary Young; Howard Minkoff; Nancy A Hessol
Journal:  Am J Med       Date:  2002-08-01       Impact factor: 4.965

2.  Osteopenia and osteoporosis in people living with HIV: multiprofessional approach.

Authors:  Ana Lucia Lei Munhoz Lima; Priscila Rosalba D de Oliveira; Perola Grimberg Plapler; Flora Maria D Andrea Marcolino; Eduardo de Souza Meirelles; André Sugawara; Riccardo Gomes Gobbi; Alexandre Leme Godoy Dos Santos; Gilberto Luis Camanho
Journal:  HIV AIDS (Auckl)       Date:  2011-12-08

3.  Trends in prevalence of selected opportunistic infections associated with HIV/AIDS in Uganda.

Authors:  John Rubaihayo; Nazarius M Tumwesigye; Joseph Konde-Lule
Journal:  BMC Infect Dis       Date:  2015-04-17       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.